A federal appeals court Sept. 19 upheld a Hybritech patent covering a method of using monoclonal antibodies in immunometric assays for the detection and monitoring of physiologically significant conditions. The Hybritech patent, no. 4,376,110, had earlier been declared invalid in federal court in Northern California under a suit filed by Hybritech against Monoclonal Antibodies, Inc. The case has been remanded to the district court to determine now whether the Hybritech patent is being infringed by Monoclonal Antibodies' manufacture and sale of immunoassay test kits.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.